The open-label trial evaluated the intravesical drug-releasing system with erdafitinib (Erda-iDRS) in non–muscle-invasive bladder cancer (NMIBC) with fibroblast growth factor receptor (FGFR) alterations.

The study involving intermediate-risk and high-risk NMIBC patients met its primary safety endpoint and indicated an 89% complete response rate, a secondary endpoint, JNJ said. Regarding the duration of complete response, another secondary endpoint, the trial demonstrated 18 months as the median duration of complete response.

In terms of safety, there were no dose-limiting toxicities, while 9% of patients discontinued the study due to adverse events. Meanwhile, 2% of the subjects experienced serious treatment-related adverse events.

J&J (JNJ) added that the results support its ongoing Phase 2 and Phase 3 studies designed to test Erda-iDRS in intermediate- and high-risk non–muscle-invasive bladder cancer.

The post J&J hits main goal in early-stage trial for drug delivery system appeared first on Up2info.com.

The company identified Tecnis PureSee as the first FDA-approved extended depth of focus intraocular lens, which maintains contrast sensitivity, an important aspect of visual quality that determines a patient’s ability to differentiate an object from its background.

Tecnis PureSee is designed to decrease patients’ dependence on glasses post-surgery, JNJ said, adding that 97% of users haven’t reported halos, glare, or other visual disturbances following its implantation.

The product expected to launch in the U.S. later this year will be the latest addition to J&J’s (JNJ) Tecnis portfolio of lenses, which includes Tecnis Odyssey IOL, a Full Visual Range IOL, and TECNIS Eyhance IOL, a monofocal IOL.

The post J&J wins FDA nod for Tecnis PureSee intraocular lens appeared first on Up2info.com.

The settlement between J&J (JNJ) units and plaintiffs, including the Government Employees Health Association, requires approval from a judge, Reuters reported, citing a court document submitted on Wednesday.

The lawsuit filed in the federal court in Maryland alleged that the companies delayed the market entry of generics against Tracleer, an oral prescription medicine used to treat pulmonary arterial hypertension.

By hindering access to samples of Tracleer, JNJ units “effectively blocked competitors from bringing a competing generic product to market for a period of time,” said the plaintiffs, a group comprising entities that purchased the medication or reimbursed their members for its costs.

The class action covers Tracleer sales that occurred in 31 states, the District of Columbia, and Puerto Rico during a period from December ​2015 to September 2024.

The post J&J subsidiaries ink $65M deal to resolve Tracleer antitrust case appeared first on Up2info.com.

The letters were

The post Pharma giants pressed by Senate Democrats over Trump pricing deals appeared first on Up2info.com.

Specifically, the FDA has greenlighted Tecvayli with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed or refractory multiple myeloma who have already received at least one line of therapy previously.

Darzalex Faspro is a subcutaneous injection developed using Halozyme’s (HALO) Enhanze drug delivery technology.

The decision marks the third drug approval under the FDA Commissioner’s National Priority Voucher pilot program, which was launched last year to expedite the review of experimental therapies developed by companies aligned with U.S. national interests.

The FDA stated that the approval came in just 55 days after J&J (JNJ) received a national priority voucher for its marketing application for the drug combo in December.

The post J&J wins FDA nod for multiple myeloma therapy appeared first on Up2info.com.

The post Kenvue effort to dismiss Tylenol case rejected by Texas judge appeared first on Up2info.com.

The post J&J seeks additional indication for Imaavy for rare type of anemia appeared first on Up2info.com.

New Jersey-based Johnson & Johnson (JNJ) defended its testing and marketing. “Litigation does not change data,” a company spokesperson told Reuters. “Our analysis was designed to meet rigorous guidance on real-world evidence, and this legal action demonstrates Bayer’s obvious misunderstanding of methodological frameworks and real-world evidence principles.”

Bayer (BAYRY) and Johnson & Johnson (JNJ) did not immediately respond to Seeking Alpha’s request for comment.

More on Johnson & Johnson, Bayer

• Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
• Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
• Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention – Slideshow
• Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
• Johnson & Johnson considering sale of orthopedics business – report

The post Bayer sues Johnson & Johnson over prostate cancer drug claims appeared first on Up2info.com.

Additionally, looking towards next week, industry players such as Johnson & Johnson (JNJ) and Delta Air Lines (DAL) will see the ex-dividend dates for their upcoming dividend payments.

See a breakdown below of some of the highlights of this week, along with some upcoming activity on the dividend front.

Dividend Increases

Here are some companies that have announced a dividend increase in the past week:

Devon Energy (DVN)

• Dividend declared: February 17
• New dividend amount: $0.78
• Previous amount: $0.73
• Increase: 6.8%

Analog Devices (ADI)

• Dividend declared: February 17
• New dividend amount: $1.10
• Previous amount: $0.99
• Increase: 11.1%

Sherwin Williams (SHW)

• Dividend declared: February 18
• New dividend amount: $0.80
• Previous amount: $0.79
• Increase: 1.3%

Dividend Declarations

Here are some companies that have announced a dividend in the past week:

GE Vernova (GEV)

• Dividend declared: February 17
• Dividend amount: $0.50

Halliburton (HAL)

• Dividend declared: February 18
• Dividend amount: $0.17

Humana (HUM)

• Dividend declared: February 19
• Dividend amount: $0.885

AbbVie (ABBV)

• Dividend declared: February 19
• Dividend amount: $1.73

Upcoming Dividend Calendar

Here are some companies that have an ex-dividend date coming next week:

Northrop Grumman (NOC)

• Ex-dividend date: February 23
• Payout date: March 11

Johnson & Johnson (JNJ)

• Ex-dividend date: February 24
• Payout date: March 10

Delta Air Lines (DAL)

• Ex-dividend date: February 26
• Payout date: March 19

Marriott International (MAR)

• Ex-dividend date: February 26
• Payout date: March 31

Additional Dividend Information

For investors looking to gain further access to the dividend space, listed below are some popular dividend-focused ETFs that can be further analyzed:

Dividend ETFs: (VIG), (SCHD), (VYM), (DGRO), (SDY), (DVY), (IDV), (DGRW), (NOBL), (HDV), (RDVY), (VIGI), and (SDVY).

The post Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more appeared first on Up2info.com.

The post Johnson & Johnson considering sale of orthopedics business – report appeared first on Up2info.com.